Cargando…
Hyperprogressive disease after avelumab maintenance therapy in a patient with advanced ureter cancer: A case report
In the early stages of immunocheckpoint inhibitor administration, we should be aware of rapid cancer progression, known as hyperprogressive disease, in real-world clinical practice. We report a case of a 73-year-old man who presented with right abdominal pain and was diagnosed with advanced right ur...
Autores principales: | Ogasawara, Keita, Ikarashi, Daiki, Tamada, Shinji, Tsuyukubo, Takashi, Fujisawa, Hiromitsu, Obara, Wataru |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9679574/ https://www.ncbi.nlm.nih.gov/pubmed/36425905 http://dx.doi.org/10.1016/j.eucr.2022.102278 |
Ejemplares similares
-
Advance renal pelvic cancer caused obstructive jaundice: A case report
por: Ikarashi, Daiki, et al.
Publicado: (2022) -
Efficacy of combination therapy with pembrolizumab and axitinib for metastatic renal collecting duct cell carcinoma: A report on two cases
por: Tamada, Shinji, et al.
Publicado: (2022) -
Complete Pathological Response to Neoadjuvant Pembrolizumab in a Patient With Chemoresistant Upper Urinary Tract Urothelial Carcinoma: A Case Report
por: Ikarashi, Daiki, et al.
Publicado: (2020) -
Hyperprogression After Immunotherapy for Primary Small Cell Neuroendocrine Carcinoma of the Ureter: A Case Report
por: Qing, Defeng, et al.
Publicado: (2021) -
Metastatic bladder cancer forming a sigmoidorectal fistula after enfortumab vedotin therapy: a case report
por: Tamada, Shinji, et al.
Publicado: (2023)